학술논문
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Document Type
Article
Author
Mansfield, A.S.; Wei, Z.; Gray, R.J.; Li, S.; Mehra, R.; Shaw, A.T.; Flaherty, K.T.; Lieu, C.H.; Forde, P.M.; Drilon, A.E.; Mitchell, E.P.; Wright, J.J.; Takebe, N.; Sharon, E.; Hovelson, D.; Tomlins, S.; Zeng, J.; Poorman, K.; Malik, N.; McShane, L.M.; Rubinstein, L.V.; Patton, D.; Williams, P.M.; Hamilton, S.R.; Conley, B.A.; Harris, L.N.; Arteaga, C.L.; O’Dwyer, P.J.; Chen, A.P.
Source
In: npj Precision Oncology . (npj Precision Oncology, December 2022, 6(1))
Subject
Language
English
ISSN
2397768X